Stay updated on Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedPublication notes were updated to state that publications are automatically filled from PubMed and may not always pertain to the study, replacing the previous longer description. The page revision tag was updated to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedA notice about potential data delays due to government funding lapses and the NIH Clinical Center's operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedResults from KEYNOTE-040 are now displayed, including OS, PFS, ORR, DOR, and safety outcomes. The new content provides outcome data for pembrolizumab versus standard treatment in recurrent/metastatic head and neck cancer.SummaryDifference0.4%

- Check71 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference2%

- Check78 days agoChange DetectedUpdate the page version from v3.0.2 to v3.1.0, reflecting a newer release metadata.SummaryDifference0.0%

- Check93 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page.